Compare Inovio Pharmaceuticals Inc (INO) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Phillips 66 — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Phillips 66 trades at $210.05 (market cap $83.72B). The key difference: Phillips 66 is far larger — about 937.8× Inovio Pharmaceuticals Inc's market cap, and Phillips 66 pays a 2.43% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PSX | |
|---|---|---|
Market Cap | $89.27M | $83.72B |
Sector | Health | Energy |
52-Week High | $2.87 | $208.80 |
52-Week Low | $1.05 | $118.37 |
Enterprise Value | $60.28M | $105.69B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PSX trades at $209.47, up 1.26% on the day, with strong technical momentum and bullish moving average signals. The stock benefits from elevated refining margins and has beaten earnings expectations in three consecutive quarters. Recent news highlights its advantage from tight fuel markets and Middle East supply dynamics, while the company maintains a solid dividend payout of $1.27 per share.
Outlook remains positive with 57% analyst buy ratings and a consensus price target of $201.50, though current price exceeds this. Risks include volatile oil prices and declining revenue trends from $170B in 2022 to $132.4B in 2025. Institutional sentiment is supported by efficient refining operations and strategic positioning in current energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
